Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

The mTOR signalling pathway in human cancer.

Pópulo H, Lopes JM, Soares P.

Int J Mol Sci. 2012;13(2):1886-918. doi: 10.3390/ijms13021886. Epub 2012 Feb 10. Review.

2.

Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations.

Moschetta M, Reale A, Marasco C, Vacca A, Carratù MR.

Br J Pharmacol. 2014 Aug;171(16):3801-13. doi: 10.1111/bph.12749. Review.

3.

Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.

Barrett D, Brown VI, Grupp SA, Teachey DT.

Paediatr Drugs. 2012 Oct 1;14(5):299-316. doi: 10.2165/11594740-000000000-00000. Review.

4.

Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.

Gibbons JJ, Abraham RT, Yu K.

Semin Oncol. 2009 Dec;36 Suppl 3:S3-S17. doi: 10.1053/j.seminoncol.2009.10.011. Review.

PMID:
19963098
5.

mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.

Wysocki PJ.

Expert Rev Mol Diagn. 2009 Apr;9(3):231-41. doi: 10.1586/erm.09.8. Review.

PMID:
19379082
6.
7.

The complexes of mammalian target of rapamycin.

Zhou H, Huang S.

Curr Protein Pept Sci. 2010 Sep;11(6):409-24. Review.

8.
9.

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.

Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM.

PLoS Biol. 2009 Feb 10;7(2):e38. doi: 10.1371/journal.pbio.1000038.

10.

Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.

Xu G, Zhang W, Bertram P, Zheng XF, McLeod H.

Int J Oncol. 2004 Apr;24(4):893-900.

PMID:
15010827
11.

The expanding role of mTOR in cancer cell growth and proliferation.

Cargnello M, Tcherkezian J, Roux PP.

Mutagenesis. 2015 Mar;30(2):169-76. doi: 10.1093/mutage/geu045. Review.

12.

Autoregulation of the mechanistic target of rapamycin (mTOR) complex 2 integrity is controlled by an ATP-dependent mechanism.

Chen CH, Kiyan V, Zhylkibayev AA, Kazyken D, Bulgakova O, Page KE, Bersimbaev RI, Spooner E, Sarbassov dos D.

J Biol Chem. 2013 Sep 20;288(38):27019-30. doi: 10.1074/jbc.M113.498055. Epub 2013 Aug 8.

13.

LKB1 and AMP-activated protein kinase control of mTOR signalling and growth.

Shaw RJ.

Acta Physiol (Oxf). 2009 May;196(1):65-80. doi: 10.1111/j.1748-1716.2009.01972.x. Epub 2009 Feb 19. Review.

14.

Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice.

Huang X, Wullschleger S, Shpiro N, McGuire VA, Sakamoto K, Woods YL, McBurnie W, Fleming S, Alessi DR.

Biochem J. 2008 Jun 1;412(2):211-21. doi: 10.1042/BJ20080557.

PMID:
18387000
15.

Loss of mTOR signaling affects cone function, cone structure and expression of cone specific proteins without affecting cone survival.

Ma S, Venkatesh A, Langellotto F, Le YZ, Hall MN, Rüegg MA, Punzo C.

Exp Eye Res. 2015 Jun;135:1-13. doi: 10.1016/j.exer.2015.04.006. Epub 2015 Apr 14.

16.

Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies.

Eyre TA, Collins GP, Goldstone AH, Cwynarski K.

Br J Haematol. 2014 Aug;166(3):336-51. doi: 10.1111/bjh.12945. Epub 2014 May 19. Review.

PMID:
24842496
17.

PI3K-p110-alpha-subtype signalling mediates survival, proliferation and neurogenesis of cortical progenitor cells via activation of mTORC2.

Wahane SD, Hellbach N, Prentzell MT, Weise SC, Vezzali R, Kreutz C, Timmer J, Krieglstein K, Thedieck K, Vogel T.

J Neurochem. 2014 Jul;130(2):255-67. doi: 10.1111/jnc.12718. Epub 2014 May 3.

18.

mTORC1- and mTORC2-interacting proteins keep their multifunctional partners focused.

Bracho-Valdés I, Moreno-Alvarez P, Valencia-Martínez I, Robles-Molina E, Chávez-Vargas L, Vázquez-Prado J.

IUBMB Life. 2011 Oct;63(10):896-914. doi: 10.1002/iub.558. Epub 2011 Sep 9. Review.

19.

RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.

Gordon BS, Kazi AA, Coleman CS, Dennis MD, Chau V, Jefferson LS, Kimball SR.

Cell Signal. 2014 Mar;26(3):461-7. doi: 10.1016/j.cellsig.2013.11.035. Epub 2013 Dec 3.

20.

A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models.

Zhang H, Berel D, Wang Y, Li P, Bhowmick NA, Figlin RA, Kim HL.

PLoS One. 2013;8(1):e54918. doi: 10.1371/journal.pone.0054918. Epub 2013 Jan 22.

Items per page

Supplemental Content

Write to the Help Desk